Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effort required to finish shotgun-generated genome sequences differs significantly among vertebrates.
Blakesley RW, Hansen NF, Gupta J, McDowell JC, Maskeri B, Barnabas BB, Brooks SY, Coleman H, Haghighi P, Ho SL, Schandler K, Stantripop S, Vogt JL, Thomas PJ; NISC Comparative Sequencing Program; Bouffard GG, Green ED. Blakesley RW, et al. BMC Genomics. 2010 Jan 11;11:21. doi: 10.1186/1471-2164-11-21. BMC Genomics. 2010. PMID: 20064230 Free PMC article.
Novel phenotypes identified by plasma biochemical screening in the mouse.
Hough TA, Nolan PM, Tsipouri V, Toye AA, Gray IC, Goldsworthy M, Moir L, Cox RD, Clements S, Glenister PH, Wood J, Selley RL, Strivens MA, Vizor L, McCormack SL, Peters J, Fisher EM, Spurr N, Rastan S, Martin JE, Brown SD, Hunter AJ. Hough TA, et al. Among authors: tsipouri v. Mamm Genome. 2002 Oct;13(10):595-602. doi: 10.1007/s00335-002-2188-1. Mamm Genome. 2002. PMID: 12420138
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL; RECITAL Investigators. Maher TM, et al. Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11. Lancet Respir Med. 2023. PMID: 36375479 Free article. Clinical Trial.
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial.
Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA. Whitty JA, et al. Among authors: tsipouri v. Eur Respir J. 2020 Feb 6;55(2):1901157. doi: 10.1183/13993003.01157-2019. Print 2020 Feb. Eur Respir J. 2020. PMID: 31699838 Free article. No abstract available.
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.
Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA. Alfieri V, et al. Among authors: tsipouri v. Eur Respir J. 2020 Feb 20;55(2):1901681. doi: 10.1183/13993003.01681-2019. Print 2020 Feb. Eur Respir J. 2020. PMID: 31699833 Free article. No abstract available.
Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.
Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA. Visca D, et al. Among authors: tsipouri v. Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28. Lancet Respir Med. 2018. PMID: 30170904 Free article. Clinical Trial.
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM. Saunders P, et al. Among authors: tsipouri v. Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2. Trials. 2017. PMID: 28619061 Free PMC article. Clinical Trial.
14 results